AI Article Synopsis

  • EGFR-TKIs like icotinib, osimertinib, and aumolertinib are effective treatments for non-small cell lung cancer (NSCLC) in patients with EGFR mutations, and anlotinib is used alongside them as an anti-angiogenic agent.
  • A new method using ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) has been developed to simultaneously measure the levels of these drugs in patient blood samples.
  • The assay has shown strong performance metrics such as selectivity, accuracy, and repeatability, confirming its reliability for clinical monitoring of these medications' concentrations in patients.

Article Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as icotinib, osimertinib, and aumolertinib have emerged as promising treatment options for EGFR mutated Non-small cell lung cancer (NSCLC) patients. Additionally, anlotinib, an anti-angiogenic agent targeting VEGFR, FGFR, and PDGFR, has been used in combination with EGFR-TKIs in NSCLC cases. A method utilizing ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed and validated for quantifying icotinib, osimertinib, aumolertinib and anlotinib simultaneously in clinical TDM. The chromatographic separation was performed using a Kinetex C18 column (100 mm × 2.1 mm) and an elution gradient of ammonium acetate in water acidified with 0.1 % formic acid and in acetonitrile. The assay was validated over a linear range of 4-2000 ng/mL for icotinib, 2-1000 ng/mL for osimertinib, 1-500 ng/mL for aumolertinib, and 0.8-400 ng/mL for anlotinib, following the guidelines on bioanalytical methods by FDA. The quantification method exhibited satisfactory performance in terms of selectivity, accuracy (from 91.3 % to 107 %), precision (intra- and inter-day coeffficients of variation ranged from 0.944 % to 7.48 %), linearity, recovery (from 86.0 % to 91.9 %), matrix effect (IS-normalized matrix factors were from 96.7 % to 102 %), and stability. Overall, the method proved to be sensitive, reliable, and straightforward, enabling successful simultaneous determination of blood concentrations of icotinib, osimertinib, aumolertinib, and anlotinib in patients. The validity of the method has been confirmed across various instruments.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2024.116445DOI Listing

Publication Analysis

Top Keywords

icotinib osimertinib
16
osimertinib aumolertinib
16
aumolertinib anlotinib
12
simultaneous determination
8
icotinib
5
osimertinib
5
aumolertinib
5
anlotinib
5
determination icotinib
4
anlotinib human
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!